NO20091771L - Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat - Google Patents

Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat

Info

Publication number
NO20091771L
NO20091771L NO20091771A NO20091771A NO20091771L NO 20091771 L NO20091771 L NO 20091771L NO 20091771 A NO20091771 A NO 20091771A NO 20091771 A NO20091771 A NO 20091771A NO 20091771 L NO20091771 L NO 20091771L
Authority
NO
Norway
Prior art keywords
hydroxyethylcarbamate
chlorophenyl
crystal
fresh crystal
fresh
Prior art date
Application number
NO20091771A
Other languages
English (en)
Inventor
Matthew Peterson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20091771L publication Critical patent/NO20091771L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

Foreliggende oppfinnelse vedrører en ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat, farmasøytiske sammensetninger omfattende denne krystall og fremgangsmåter for å fremstille og anvende denne krystall.
NO20091771A 2006-10-06 2009-05-05 Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat NO20091771L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82839206P 2006-10-06 2006-10-06
PCT/US2007/021502 WO2008045391A2 (en) 2006-10-06 2007-10-05 Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate

Publications (1)

Publication Number Publication Date
NO20091771L true NO20091771L (no) 2009-05-05

Family

ID=39283405

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091771A NO20091771L (no) 2006-10-06 2009-05-05 Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat

Country Status (19)

Country Link
US (1) US7632963B2 (no)
EP (1) EP2076258A4 (no)
JP (1) JP2010505856A (no)
KR (1) KR20090076958A (no)
CN (1) CN101657195A (no)
AU (1) AU2007307029A1 (no)
BR (1) BRPI0718131A2 (no)
CA (1) CA2665573A1 (no)
CO (1) CO6180504A2 (no)
CR (1) CR10764A (no)
EA (1) EA200970355A1 (no)
GT (1) GT200900076A (no)
IL (1) IL198016A0 (no)
MX (1) MX2009003755A (no)
NI (1) NI200900050A (no)
NO (1) NO20091771L (no)
SV (1) SV2009003211A (no)
WO (1) WO2008045391A2 (no)
ZA (1) ZA200903095B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
KR101795562B1 (ko) * 2011-12-27 2017-11-08 (주)바이오팜솔루션즈 뇌졸중의 치료 또는 예방에 사용되는 페닐카바메이트 화합물
US12054449B2 (en) 2021-08-05 2024-08-06 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate crystalline form and method for manufacturing the same
WO2023014160A1 (ko) * 2021-08-05 2023-02-09 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법
KR102399807B1 (ko) * 2021-08-05 2022-05-20 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698588A (en) 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
CN1176654C (zh) * 1999-09-10 2004-11-24 大日本油墨化学工业株式会社 喹啉酮衍生物制剂及其制法
IL157591A0 (en) * 2001-02-27 2004-03-28 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating neurodegenerative disorders
CZ2004718A3 (cs) * 2001-12-21 2004-12-15 Ortho-Mc-Neil Pharmaceutical, Inc. Způsob přípravy 2-(substituovaný fenyl)-2-hydroxyethylkarbamátů
PL1658277T3 (pl) * 2003-08-18 2012-10-31 H Lundbeck As Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
HRP20100304T1 (hr) * 2004-09-16 2010-09-30 Janssen Pharmaceutica Nv Uporaba 2-fenil-1,2-etanediol-(di)karbamata za liječenje epileptogeneze
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Also Published As

Publication number Publication date
MX2009003755A (es) 2009-07-10
SV2009003211A (es) 2009-11-24
EA200970355A1 (ru) 2009-12-30
IL198016A0 (en) 2009-12-24
NI200900050A (es) 2010-02-01
CR10764A (es) 2009-09-14
WO2008045391A3 (en) 2008-06-12
EP2076258A2 (en) 2009-07-08
CA2665573A1 (en) 2008-04-17
ZA200903095B (en) 2010-07-28
US7632963B2 (en) 2009-12-15
BRPI0718131A2 (pt) 2013-11-05
CN101657195A (zh) 2010-02-24
WO2008045391A2 (en) 2008-04-17
GT200900076A (es) 2010-05-18
CO6180504A2 (es) 2010-07-19
US20080085930A1 (en) 2008-04-10
KR20090076958A (ko) 2009-07-13
EP2076258A4 (en) 2011-09-28
AU2007307029A1 (en) 2008-04-17
JP2010505856A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EA201070786A1 (ru) Бензофуропиримидиноны
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
PH12014500053A1 (en) Proteasome inhibitors
NO20092637L (no) Fremgangsmater for behandling
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
EA200970156A1 (ru) Пиридизиноновые производные
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
NO20090596L (no) Antivirale fosfinatforbindelser
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
EA201170703A1 (ru) Производные адамантилбензамида
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
WO2008061108A3 (en) Phthalazine derivatives
EA201000814A1 (ru) 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
TW200621721A (en) Methods of preparing indazole compounds
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application